U.S. markets open in 8 hours 34 minutes
  • S&P Futures

    4,360.50
    -43.25 (-0.98%)
     
  • Dow Futures

    34,002.00
    -251.00 (-0.73%)
     
  • Nasdaq Futures

    14,318.50
    -182.50 (-1.26%)
     
  • Russell 2000 Futures

    2,007.90
    -23.80 (-1.17%)
     
  • Crude Oil

    83.64
    +0.33 (+0.40%)
     
  • Gold

    1,842.50
    +0.80 (+0.04%)
     
  • Silver

    23.84
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1325
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • Vix

    29.90
    +1.05 (+3.64%)
     
  • GBP/USD

    1.3481
    -0.0009 (-0.07%)
     
  • USD/JPY

    113.9060
    -0.0540 (-0.05%)
     
  • BTC-USD

    36,087.52
    +109.62 (+0.30%)
     
  • CMC Crypto 200

    821.53
    +10.93 (+1.35%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,113.13
    -475.24 (-1.72%)
     

Kezar Life Sciences to Participate in the William Blair Biotech Focus Conference 2021

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • KZR

SOUTH SAN FRANCISCO, Calif., July 08, 2021--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced its Co-founder and Chief Scientific Officer, Christopher Kirk, will participate in the "Novel Targets for Autoimmune Diseases" panel discussion at William Blair's Biotech Focus Conference on Thursday, July 15, 2021, at 11:00 a.m. ET.

A live webcast of the panel may be accessed at the "Events & Presentations" section of Kezar’s website at http://investors.kezarlifesciences.com/events. Kezar Life Sciences will maintain an archived replay of the webcast on its website for 90 days after the conference.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company bringing novel treatments to patients with rare autoimmune diseases and cancer. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. KZR-616, its lead development candidate, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. Additionally, KZR-261, the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway, is undergoing IND-enabling activities. For more information, visit www.kezarlifesciences.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005060/en/

Contacts

Argot Partners
212-600-1902
kezar@argotpartners.com